- Home
- LFS vs HURA Comparison
LFS vs HURA Comparison
Compare LFS & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LFS | HURA |
|---|---|---|
| Founded | 2001 | 2009 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.3M | 131.8M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | LFS | HURA |
|---|---|---|
| Price | $4.05 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | ★ 2.6M | 447.0K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 99.16 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $76,556,507.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.64 | ★ N/A |
| Revenue Growth | ★ 12.13 | N/A |
| 52 Week Low | $1.58 | $0.97 |
| 52 Week High | $12.49 | $5.99 |
Technical Indicators
Market Signals| Indicator | LFS | HURA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 25.42 |
| Support Level | N/A | $0.97 |
| Resistance Level | N/A | $2.02 |
| Average True Range (ATR) | 0.00 | 0.19 |
| MACD | 0.00 | -0.09 |
| Stochastic Oscillator | 0.00 | 4.47 |
Price Performance
Historical ComparisonAbout LFS LEIFRAS Co. Ltd. American Depositary Shares
Leifras Co Ltd is a sports and social business company dedicated to youth sports and community engagement. It provide services related to the organization and operations of sports schools and sports events for children.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.